Status:

COMPLETED

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Lead Sponsor:

AstraZeneca

Conditions:

Hyperkalemia

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This is a single center, inpatient, open label pharmacodynamic study to determine the effect of 5 g and 10 g doses of Sodium Zirconium Cyclosilicate (ZS) administered once daily (qd) for 4 days on pot...

Detailed Description

This study will be conducted at 1 study centre in Hong Kong. Approximately 22 Subjects will be screened to achieve 20 subjects completing the study. Subjects will be randomized to receive ZS 5 g or 10...

Eligibility Criteria

Inclusion

  • Key
  • Provision of informed consent prior to any study specific procedures
  • Female and/or male healthy Chinese subjects aged between 18 and 55 inclusive who reside in Hong Kong
  • Ability to have repeated blood draws or effective venous catheterization
  • Willing to consume food and beverages using a standardized daily diet containing 40 (± 10%) mEq/day sodium and 128 (± 10%) mEq/day potassium provided by the research site
  • Key

Exclusion

  • Participation in another clinical study with an investigational product during the last 3 months
  • Subjects who were receiving concomitant medications including vitamins, dietary supplements and herbal preparations within 2 weeks prior to Study Day 1 of the Diet Run-in Period.
  • Current and/or past history of alcohol abuse within the past year or a positive results (exceed normal range) of breath test for alcohol abuse
  • Current and/or past history of drugs abuse within the past year or a positive drug abuse screen, e. g. methylenedioxymethamphetamine, opiate, barbiturates, benzodiazepines, ketamine, cocaine, amphetamine, methamphetamine, marijuana, and methadone.
  • Plasma donation within 1 month of screening or any blood donation/blood loss \>500 mL during the 3 months prior to screening.

Key Trial Info

Start Date :

October 24 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 23 2017

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT03283267

Start Date

October 24 2017

End Date

November 23 2017

Last Update

December 19 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Hong Kong, Hong Kong